OpGen Announces Date of 2016 Fourth Quarter and Year End Financial Results Conference Call
Mar 16, 2017 20:30 pm UTC| Business
GAITHERSBURG, Md., March 16, 2017 -- OpGen, Inc. (NASDAQ:OPGN) today announced that it will report its 2016 fourth quarter and year end financial results after close of market Thursday, March 23, 2017. OpGen’s...
Mar 16, 2017 20:30 pm UTC| Business
Wilmington, Delaware, March 16, 2017 -- The report “2017-2022 Global Top Countries Sodium Bicarbonate Food Grade Market Report”, available on MarketIntelReports, estimates that Latin America and Asia-Pacific markets...
Mar 16, 2017 20:30 pm UTC| Business
PRINCETON, N.J., March 16, 2017 -- Agile Therapeutics, Inc. (Nasdaq:AGRX), a women’s healthcare company, announced a poster presentation of data from the SECURE Phase 3 clinical trial for its lead product candidate,...
Miramar Labs, Inc.® Reports Fourth Quarter and Full Year 2016 Financial Results
Mar 16, 2017 20:22 pm UTC| Business
Highlights: 2016 revenue of $20.4 million, up 19% year-over-yearStrong sales in North America with year-over-year growth of 38%Gross margin expands to 55% in 2016, up from 52% in the prior year SANTA CLARA, Calif.,...
GSV Capital Corp. Reports Fourth Quarter and Fiscal Year 2016 Financial Results
Mar 16, 2017 20:20 pm UTC| Business
WOODSIDE, Calif., March 16, 2017 -- GSV Capital Corp. (“GSV Capital” or the “Company”) (Nasdaq:GSVC) today announced financial results for the quarter and fiscal year ended December 31, 2016. Net assets totaled...
Mar 16, 2017 20:18 pm UTC| Business
ATHLONE, Ireland, March 16, 2017 -- Innocoll Holdings plc (Nasdaq:INNL), a global, commercial stage, specialty pharmaceutical company with late stage development programs targeting areas of significant unmet medical...
KalVista Pharmaceuticals Reports Fiscal Third Quarter Results
Mar 16, 2017 20:15 pm UTC| Business
– Continuing to Develop a Portfolio of Oral Plasma Kallikrein Inhibitors for HAE –– Intravitreal DME Program Remains on Track for Phase 2 in 2017 –– Company Expects to be Well-Funded Through Data Inflection Points...